CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 30 enrolled
Drug / intervention
human retinal progenitor cellsbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04604899
NCT04604899Phase 2Completed
CompareCT.gov

A Phase 2 Study of the Safety of Repeat Intravitreal Injection of Human Retinal Progenitor Cells (jCell) in Adult Subjects With Retinitis Pigmentosa (RP)

jCyte, Inc·interventional·Posted Oct 27, 2020·Updated Jul 16, 2024

In Brief

A Phase 2 clinical trial evaluating human retinal progenitor cells for Retinitis Pigmentosa. Completed, enrolled 30 participants across 3 sites.

Detailed Summary

The primary objective of the study is to assess the safety of repeat injection of human retinal progenitor cells (jCell) in adult subjects with RP that have previously been treated with jCell.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRetinitis Pigmentosa
CountriesUnited States
CollaboratorsCalifornia Institute for Regenerative Medicine (CIRM)

Timeline

Phase 2CompletedFinished
202120222023202420252026
First PostedOct 27, 2020
Enrollment StartDec 1, 2020
Primary CompletionMar 22, 2022
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 5.7 years ago

Interventions

human retinal progenitor cellsbiological

single intravitreal injection of 6.0 million human retinal progenitor cells (hRPC)